Abstract: The base sequence for the expression of a therapeutic gene and the medicament for gene therapy are disclosed. There is also disclosed the base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. Moreover, there is disclosed the medicament for gene therapy containing a therapeutic gene downstream any of the above-mentioned base sequences, capable of directing the expression of the therapeutic gene specifically to squamous epithelium.

Abstract: The invention provides solid preparations for oral administration of gene-related drugs comprising a core containing the gene-related drug with a coating which does not disintegrated in small intestines, wherein said preparations can be easily tabletted, remain stable during the preparation process and said drug can be efficiently absorbed in digestive tracts.

Abstract: Provide milk powders for confectionery and bakery products that, when added during the production of confectionery and bakery products, can increase the volume of breads, pancakes, cakes, pies, etc., and further add a desirable texture and feel in the mouth to breads, pancakes and cakes. Obtain milk powders for confectionery and bakery products containing 4 to 10 weight-percent of non-protein nitrogen (based on the weight of converted protein) and 1 to 20 weight-percent of ash in a manner keeping the ratio of non-protein nitrogen to total nitrogen to 0.5 or less, by intermixing, as appropriate, dairy ingredients containing non-protein nitrogen with other dairy ingredients such as whole milk powders, skim milk powders, buttermilk powders, whey powders, milk minerals, whey protein concentrates and milk protein concentrates.

Abstract: A crosslinked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having a vinyl group capable of reacting in Michael addition reaction and a carboxylic ester group, and thus by making the amino and/or imino groups contained in the polymer (A) add to the vinyl group in the compound (B) and form a amide-bond with the carboxylic ester group in the compound (B).

Abstract: There are provided immunosuppressants with few side effects that can be used to suppress rejection involving organ transplantation, and the immunosuppressants comprising antibodies against histone H1 which specifically recognize antigenic proteins may be used to suppress immunity in mammals for treatment or prevention of rejection involving organ transplantation.

Abstract: There are disclosed polypeptide derivatives and their pharmaceutically acceptable salts represented by formula (1), as well as their utility as nucleic acid carriers in gene therapy.

Abstract: Medicinal compositions for colorectal cancer to be administered to the large intestine by taking advantage of preparations disintegrating in the large intestine, characterized by containing a cyclooxygenase inhibitor and an HMG-CoA reductase inhibitor. These compositions are appropriate for inhibiting the postoperative liver metastasis and recurrence of colorectal cancer.

Abstract: An absorption enhancer for the large intestine most suitable for an oral preparation, with a disintegration property in the large intestine, especially the absorption enhancer for the large intestine mixed with a hydrophilic medium and an absorption enhancer is provided.

Abstract: Novel medicinal compositions aiming at delivering a medicine to a specific site of the large intestine; and preparations for intestinal administration with the use of the same. Namely, medicinal compositions, whereby a medicine can be delivered to a specific site of the large intestine, characterized by containing a P-glycoprotein modifier; and preparations for intestinal administration with the use of the same.

Abstract: A novel nucleic acid carrier and a pharmaceutical composition for gene therapy are disclosed. The nucleic acid carrier of this invention is characterized by containing a polypeptide comprising diaminobutyric acid with a suitable number of residues and/or a pharmaceutically acceptable salt thereof. The nucleic acid carrier of this invention can form a complex with a variety of therapeutic genes that is safe and has extremely low immunogenicity (the pharmaceutical composition of this invention); and it can allow the therapeutic gene to be introduced into cells efficiently and safely whereby high expression of the gene in the cells can be realized.

Abstract: This invention relates to a gene therapeutic agent comprising indoleamine 2,3-dioxygenase (IDO) and to an immunosuppresant comprising an IDO protein, both of which are particularly effective for rejection in organ transplantation. Further, it is possible to suppress the rejection more effectively by forming a complex between the IDO gene and a gene carrier.

Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.

Abstract: An cross-linked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having two or more functional groups capable of reacting with amino and/or imino group contained in the polymer (A). The resin or salt has a water absorption ratio of 4.0 or lower.

Abstract: Agents potentiating nerve growth factor activity are provided for treating Alzheimer's disease which contain as the active ingredient dodecatrienoic acid derivatives represented by the general formula (I): 1

Abstract: Physiologically active peptides possessing cell adhesion inhibitory activity are provided. A physiologically active peptide of this invention is characterized by possessing cell adhesion inhibitory activity and comprising 30 amino acid residues or less, as well as by having an amino acid sequence of the formula: Gly Leu Lys Pro Gly Val Asp X1 Thr Ile Thr X2 X3 Ala X4 wherein X1 represents Tyr or Ala; X2 represents Val or Ala; X3 represents Tyr or Ala; and X4 represents Val or Ala.

Abstract: An optical pickup dustproofing mechanism having a simple structure is provided in which an objective lens is shielded promptly and reliably and adhesion of dust or the like to the objective lens is prevented. A movable portion 34 is able to move along a shaft center direction of a clamper 26. Further, the movable portion 34 is connected to the clamper 26 so as to face a standby position of an optical pickup 20. When a disc 14 is not placed on a turn table 18, the movable portion 34 moves downwardly and shields the objective lens 22 positioned in the standby position. Since adhesion of dust or the like to the objective lens 22 is prevented, the amount of light transmitted onto a photodetector does not decrease and reading failure is prevented. Since the present invention is simply structured such that the movable portion 34 is connected to the clamper 26, as compared to a conventional dustproofing mechanism, the number of components decreases and the structure is simplified.

Abstract: An antisense oligonucleotide characterized in that it hybridizes specifically with chromosomal DNA and/or RNA encoding CXCR4 protein to thereby inhibit the expression of the CXCR4 protein, and a HIV infection inhibitor comprising the antisense oligonucleotide, are disclosed.

Abstract: A screen has a screen main body, a power supply and a voltage regulator. The screen main body has a Fresnel lens, a polymer dispersed liquid crystal unit and a lenticular lens. The liquid crystal unit includes a polymer dispersed liquid crystal and a pair of transparent electrodes which sandwich the polymer dispersed liquid crystal. By operating the voltage regulator, a voltage applied to the electrodes is adjusted so that a gain of the liquid crystal is controlled.

Abstract: A carrier for stabilizing a nucleic acid is provided which forms a soluble, stable complex with a nucleic acid, which has a stabilizing effect on a double or triple helix of a nucleic acid, which suppresses the structural change of a nucleic acid, and which enables the reversibility of a nucleic acid to be retained. A method for stabilizing a nucleic acid by use of such a carrier is also provided. This carrier is a polymer having a poly(cationic amino acid) as a main chain, and a comb-shaped hydrophilic group as a side chain modifying the polymer.

Abstract: A screen has a screen main body, a power supply and a voltage regulator. The screen main body has a Flesnel lens, a polymer dispersed liquid crystal unit and a lenticular lens 15. The liquid crystal unit includes a polymer dispersed liquid crystal and a pair of transparent electrodes which sandwich the polymer dispersed liquid crystal. By operating the voltage regulator, a voltage applied to the electrodes is adjusted so that a gain of the liquid crystal is controlled.